Stem Cell Medicine (SCM) Receives Israeli Government Funding for Gene Therapy Facility

▤ Summary

The first gene therapy product under development at SCM is for the treatment of neuropathic pain. Ehud Marom, SCMs Chairman, said, "We are pleased that the government of Israel recognizes our unique contribution to the development of new therapies. There is, however, a global bottleneck in GMP approved labs and production facilities for gene therapy and our goal is to help address this with this new investment. The new facility will enable us to further integrate our capabilities, adding gene delivery vehicles for genetic modification for human use. The Company, headquartered in Jerusalem, was founded by an experienced team of entrepreneurs from the life science and pharmaceutical industries.

$ Funding

▦ Linked Companies